Finally, we combined Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) analyses to identify that Gemcitabine acts to simulate the GDF15 gene profile and is a potential candidate for the treatment of COAD. The gene discussed is GDF15; the disease is colon adenocarcinoma.